Cystoid Macular Edema Clinical Trial
Official title:
Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma
Glaucoma, a progressive optic disc neuropathy causing visual field reduction, is the second leading cause of world blindness. The treatment of glaucoma is mainly based in reducing intraocular pressure (IOP) with topical medications. Many patients required two or more medications to achieve a target IOP. Combinations of B-blockers and prostaglandin analogs (PGA) are frequently used in clinical practice because their additive effect in lowering IOP levels. The aim of this study was to investigate the effects of fixed combinations of timolol maleate and PGA on the blood-aqueous barrier and evaluate the measurement of foveal thickness in pseudophakic patients with primary open-angle glaucoma (POAG).
Most studies found a lower incidence of systemic and ocular adverse events with fixed combinations than with the unfixed combinations. Fixed combinations are better tolerated than their respective prostaglandin analogue. However, among the most serious side effects induced by PGA are the breaking down of the blood-aqueous barrier (BAB) and the development of cystoids macular edema (CME). Also, timolol maleate drops increase protein concentration in the human and benzalkonium chloride, eye drops preservative induces anterior chamber inflammation. This randomized, masked-observer, prospective clinical trial was approved by the Ethics Committee of the University of Campinas, and it adhered to the tenets of the Declaration Of Helsinki. Written informed consent was obtained from each patient. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00508040 -
Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a
|
Phase 2 | |
Terminated |
NCT00114062 -
Study to Treat Uveitis Associated Macular Edema
|
Phase 2 | |
Completed |
NCT03025945 -
Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo
|
N/A | |
Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
Withdrawn |
NCT02598869 -
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
|
Phase 4 | |
Terminated |
NCT04527523 -
Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only
|
||
Completed |
NCT02294656 -
Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide
|
Phase 1 | |
Withdrawn |
NCT00406172 -
Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
|
Phase 3 | |
Not yet recruiting |
NCT04856670 -
Assessing Diabetes Mellitus on Cytokine Analysis and Macular Edema Following FLACS
|
||
Completed |
NCT02609165 -
Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
|
Phase 2 | |
Withdrawn |
NCT00438243 -
Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.
|
Phase 2 | |
Completed |
NCT00464581 -
Lucentis for Treatment of Macular Edema
|
N/A | |
Active, not recruiting |
NCT03465124 -
Evaluation of Central Macular Thickness in Femtosecond Laser-assisted Cataract Surgery
|
N/A | |
Recruiting |
NCT02486484 -
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
|
Phase 2 | |
Completed |
NCT00790803 -
Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
|
N/A | |
Recruiting |
NCT04225611 -
Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema
|
Phase 1/Phase 2 | |
Completed |
NCT05832996 -
Cool vs Room-temperature Artificial Tears
|
Phase 4 | |
Completed |
NCT05615805 -
The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections
|
N/A | |
Completed |
NCT00494494 -
Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
|
Phase 4 | |
Terminated |
NCT00346983 -
Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics
|
Phase 1/Phase 2 |